Mid-Year Report — BIOGEN for BIOGEN (2007)

Firm

BIOGEN

Client

BIOGEN

Income

—

Expenses

$620,000

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Patent Reform (HR. 1908 and S. 1145)

Lobbyist	Covered position, as disclosed
KATHLEEN TREGONING	STAFF MBR. HEALTH SUBCOMMITTEE WAYS& MEANS

Contacted: SENATE; Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: S. 1145 (110th), H.R. 1908 (110th)

Health Issues HCR

1) Follow-on Biologics (H.R. 1038/S. 623, H.R. 1956) 2) PDUFA/Drug Safety (S. 1082, H.R. 2900, Drug Safety Provisions) 3) AHRQ report ("The clinical effectiveness and cost effectiveness of interferon-beta and glatiramer acetate in the mgmt. of relapsing/remitting and secondary-progressive M.S.")

Lobbyist	Covered position, as disclosed
KATHLEEN TREGONING	STAFF MBR. HEALTH SUBCOMMITTEE WAYS& MEANS

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS)

Bills named: S. 623 (110th), H.R. 1038 (110th), H.R. 1956 (110th), S. 1082 (110th), H.R. 2900 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.